Publication date: January 2018
Source:Surgical Oncology Clinics of North America, Volume 27, Issue 1
Author(s): Julie Grossman, Cynthia Ma, Rebecca Aft
Teaser
Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.http://ift.tt/2yuw84W
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου